Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Januvia Jitters: FDA Warns Blockbuster Diabetes Drug May Cause Pancreatitis

This article was originally published in The Pink Sheet Daily

Executive Summary

Scrutiny of Merck’s Januvia could raise more questions about Onglyza and other DPP-4 inhibitors.

You may also be interested in...



Medco Study Lets Januvia And Byetta Off The Hook For Pancreatitis

Pharmaceutical benefits manager's review of almost 800,000 claims does not show higher risk for these two drugs, despite label warnings.

Medco Study Lets Januvia And Byetta Off The Hook For Pancreatitis

Pharmaceutical benefits manager's review of almost 800,000 claims does not show higher risk for these two drugs, despite label warnings.

FDA's Handling Of Byetta Pancreatitis Risk Could Bode Well For Other Diabetes Drugs

Amylin's Byetta cleared for first-line use without a black box stigma, but sales may still not get a lift.

Topics

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel